XSHE
000153
Market cap358mUSD
Jul 10, Last price
5.49CNY
1D
4.97%
1Q
-17.81%
Jan 2017
-57.41%
IPO
-35.18%
Name
Anhui Fengyuan Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Hefei, China in 1997, Anhui Fengyuan Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of a wide array of medicinal products. The company primarily serves the Chinese market, offering biological pharmaceuticals, chemical drugs, and traditional Chinese medicines. Its extensive product portfolio addresses numerous health concerns, including pain and fever relief, cardiovascular conditions, infections, neurological disorders, cancer, ulcers, and hormonal imbalances. Fengyuan Pharmaceutical also produces nutritional supplements, treatments for vitamin and mineral deficiencies, anti-parasitic and antimicrobial agents, coenzymes, antiviral medications, and uterine contractants. Furthermore, its offerings encompass sedative-hypnotics, drugs for irritable bowel syndrome, hypertension treatments, and remedies for benign prostatic hyperplasia. Beyond its domestic operations, the company exports its pharmaceutical goods to international markets such as Europe, North America, Africa, Southeast Asia, and Central Asia.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||